Mercilon Tafla 150 míkróg/20 míkróg Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

mercilon tafla 150 míkróg/20 míkróg

n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg

Vidisic Augnhlaup 2 mg/g Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

vidisic augnhlaup 2 mg/g

gerhard mann dr., chem.-pharm. fabrik gmbh - carbomerum inn - augnhlaup - 2 mg/g

Hyprosan (Hypromellose) Augndropar, lausn 3,2 mg/ml Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

hyprosan (hypromellose) augndropar, lausn 3,2 mg/ml

santen oy - hypromellosum inn - augndropar, lausn - 3,2 mg/ml

Oftagel Augnhlaup 2,5 mg/g Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

oftagel augnhlaup 2,5 mg/g

santen oy* - carbomer - augnhlaup - 2,5 mg/g

Oftagel Augnhlaup í stakskammtaíláti 2,5 mg/g Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

oftagel augnhlaup í stakskammtaíláti 2,5 mg/g

santen oy* - carbomer - augnhlaup í stakskammtaíláti - 2,5 mg/g

Oculac Augndropar, lausn 5 % Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

oculac augndropar, lausn 5 %

alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %

Oculac án rotvarnar Augndropar, lausn 5 % Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

oculac án rotvarnar augndropar, lausn 5 %

alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %

Bleomycin Baxter Stungulyfs-/innrennslisstofn, lausn 15.000 a.e. Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

bleomycin baxter stungulyfs-/innrennslisstofn, lausn 15.000 a.e.

baxter medical ab* - bleomycinum súlfat - stungulyfs-/innrennslisstofn, lausn - 15.000 a.e.

Ikervis Європейський Союз - ісландська - EMA (European Medicines Agency)

ikervis

santen oy - ciclosporin - kviðsjúkdómar - augnlækningar - meðferð við alvarlegum glærubólgu hjá fullorðnum sjúklingum með þurr auganu, sem hefur ekki batnað þrátt fyrir meðferð með tárubólgu.

Blenrep Європейський Союз - ісландська - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - mergæxli - Æxlishemjandi lyf - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.